Eli Lilly and Company (NYSE: LLY) has officially announced the launch of Lilly Employer Connect, a groundbreaking platform designed to bridge the significant access gap in U.S. obesity care. By partnering with over fifteen independent program administrators, Lilly aims to provide employers with flexible, transparent, and affordable pathways to provide chronic weight management treatments for their workforce.
Addressing the Obesity Crisis and Coverage Gap
Obesity currently affects more than 100 million adults in the United States, placing a staggering $1.7 trillion annual burden on the economy through direct medical costs and lost productivity. Despite its classification as a chronic disease, insurance coverage remains inconsistent. Currently, approximately half of all commercially insured employees in the U.S. lack covered access to essential obesity management medications.
Strategic Partnerships and Transparent Pricing
The platform’s strength lies in its diverse network of independent program administrators and pharmacy partners. These include organizations such as Mark Cuban Cost Plus Drug Company, 9amHealth, Calibrate Health, and HealthDyne, among others. This structure allows employers to tailor their benefits programs to their specific budget and workforce needs, whether they require low-cost administration or comprehensive, “wraparound” support services like virtual clinical care and behavioral coaching.
Read More: Eli Lilly Cuts Zepbound Prices for Self-Pay Patients Following White House Deal
As part of the launch, Lilly is offering Zepbound® (tirzepatide) KwikPen® to network pharmacies at a discounted price of $449 for all doses. While the final cost to the employer and employee may vary based on the specific program administrator and cost-sharing model chosen, this initiative provides a clear and predictable baseline for weight management expenses.
Merck KGaA Announces Silence Therapeutics Acquisition to Add Divesiran siRNA Therapy to Rare Disease Pipeline
The Silence Therapeutics acquisition gives Merck KGaA, Darmstadt, Germany, the Phase 3-ready siRNA therapy Divesiran for polycythemia vera. The deal carries a $1.1 billion enterprise […]
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, […]
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regeneron says the CHMP has recommended EU approval of an alternative Libtayo dosing schedule: 700 mg every six weeks after an initial 12-week regimen of […]
Scaling Access Through Innovation
Lilly Employer Connect is designed to evolve. The company plans to continuously expand its list of program administrators, which already features notable names such as:
- 9amHealth
- Mark Cuban Cost Plus Drug Company
- GoodRx
- Calibrate Health
- eMed
- Form Health
- ReviveHealth
By decoupling obesity care from traditional, often restrictive benefit designs, Lilly is empowering employers to prioritize long-term employee health and productivity through sustainable, evidence-based medical interventions.
